Potential benefit - A patient whose biomarkers suggest rapid metabolism of GLP-1 drugs might be offered a longer-acting formulation, while someone with strong GIP responsiveness could start on a dual-agonist right away, avoiding months of trial-and-error
Sedlak TW, Paul BD, Parker GM, Hester LD, Snowman AM, Taniguchi Y, Kamiya A, Snyder SH, Sawa A
The FDA recommends verifying that any online pharmacy is properly licensed before you purchase any medication
These may need quick medical attention
Furthermore, GLP-1RAs have been shown to positively influence body weight and metabolic control, which are critical factors in managing patients at risk of developing HCC (Wang et al., 2024)
Other common gastrointestinal effects include abdominal pain, bloating and early satiety